LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis

Abstract

Background Accumulating studies indicated that dysregulated long non-coding RNA human histocompatibility leukocyte antigen (HLA) Complex P5 (HCP5) may functions as an potential prognostic predictor in multiple cancers. This meta-analysis was performed to systematically collect studies and conduct an evidence-based evaluation of the prognostic role of HCP5 in malignancies. Methods Four databases (PubMed, Web of Science, Embase and Cochrane library) were comprehensively retrieved from their initiation date to November 9, 2021. Hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) were used to assess the associations between the expression level of HCP5 and prognosis or clinical characteristics. Moreover, results were validated by Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and the National Genomics Data Center (NGDC). Subsequently, the molecular mechanism of HCP5 was predicted based on MEM and StarBase databases. The study protocol was registered at PROSPERO (ID: CRD42021274208). Results 9 studies, containing 641 patients, were included in this meta-analysis. Our results revealed that HCP5 overexpression was associated with poor overall survival (OS), tumor type, histological differentiation, and lymph node metastasis in most cancers, but was not associated with age, gender and tumor size; down-regulation of HCP5 was associated with worse OS, advanced tumor stage, positive distal metastasis and lymph node metastasis in skin cutaneous melanoma (SKCM). HCP5 was significantly up-regulated in four cancers and down-regulated in SKCM, which was validated by the GEPIA2 cohort. HCP5 expression in various types of cancer was also verified in NGDC. Further functional prediction revealed that HCP5 may participate in some cancer-related pathways. Conclusion There is a significantly association between dysregulation of HCP5 and both prognosis and clinicopathological features in various cancers. HCP5 may be functions as a novel potential prognostic biomarker and therapeutic target in multiple human cancers.

miR-17-5p/HOXA7 Is a Potential Driver for Brain Metastasis of Lung Adenocarcinoma Related to Ferroptosis Revealed by Bioinformatic Analysis

“…HCP5 affects tumor progression differently depending on the type of malignancies. Several studies have explored the relationship between HCP5 and metastasis and prognosis in cancer ( 64 ). It was reported by Jiang et al that HCP5 was highly expressed in tumor tissues of LUAD patients and contributed to epithelial-mesenchymal transition (EMT) of LUAD cells, tumor growth, and metastasis, and was positively correlated with poor patient prognosis ( 65 ).…”

A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers

“…The field of lncRNAs had received a lot of press attention lately because of the accelerated advancement of high-throughput sequencing technologies ( Müller et al, 2015 ). Numerous studies have demonstrated that lncRNAs are implicated in tumorigenesis and development and are closely related to the prognosis of patients with tumors ( Ge et al, 2018 ; Hu et al, 2021 ). In previous meta-analyses, FOXP4-AS1 ( Zhang et al, 2022b ), SNHG15 ( Chen C. et al, 2020 ) and SNHG17 ( Zhang et al, 2022a ) were all linked to the clinicopathological characteristics and prognosis of various malignancies.…”

Long Noncoding RNA LINC02249 Is a Prognostic Biomarker and Correlates with Immunosuppressive Microenvironment in Skin Cutaneous Melanoma

“…It is important to highlight that abnormal regulation of lncRNAs has been linked to the development and progression in a variety of human cancers [12,13]. Several lncRNAs, such as lncRNA HCP5, lncRNA TEX41, and lncRNA TTN-AS1, play important roles in the growth of malignant cells in SKCM [14][15][16]. In addition, there are a growing number of studies that point to the fact that abnormally expressed lncRNAs have been utilized as possible biomarkers for the diagnosis and prognosis of cancer [17,18].…”